{
    "root": "48d58ab4-2d5c-4ac2-a2f3-a8b5163f0f28",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Levetiracetam",
    "value": "20250318",
    "ingredients": [
        {
            "name": "LEVETIRACETAM",
            "code": "44YRR34555",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6437"
        },
        {
            "name": "SILICA",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "PEG-90",
            "code": "4R4HFI6D95"
        },
        {
            "name": "PVP",
            "code": "FZ989GH94E"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "CI 77891",
            "code": "15FIX9V2JP"
        },
        {
            "name": "D&C YELLOW NO. 10 ALUMINUM LAKE",
            "code": "CQ3XH3DET6"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        }
    ],
    "indications": {
        "text": "levetiracetam indicated treatment partial-onset seizures patients 1 month age older ( 1.1 ) levetiracetam indicated adjunctive therapy treatment : myoclonic seizures patients 12 years age older juvenile myoclonic epilepsy ( 1.2 ) primary generalized tonic-clonic seizures patients 6 years age older idiopathic generalized epilepsy ( 1.3 )",
        "doid_entities": [
            {
                "text": "juvenile myoclonic epilepsy (DOID:4890)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4890"
            },
            {
                "text": "myoclonic epilepsy (DOID:308)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_308"
            },
            {
                "text": "epilepsy (DOID:1826)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1826"
            },
            {
                "text": "idiopathic generalized epilepsy (DOID:1827)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1827"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "oral solution pediatric patients body weight \u2264 20 kg ( 2.1 ) pediatric patients , weight-based dosing oral solution calibrated measuring device ( household teaspoon tablespoon ) ( 2.1 ) partial-onset seizures ( monotherapy adjunctive therapy ) 1 month < 6 months : 7 mg/kg twice daily ; increase 7 mg/kg twice daily every 2 weeks recommended dose 21 mg/kg twice daily ( 2.2 ) 6 months < 4 years : 10 mg/kg twice daily ; increase 10 mg/kg twice daily every 2 weeks recommended dose 25 mg/kg twice daily ( 2.2 ) 4 years < 16 years : 10 mg/kg twice daily ; increase 10 mg/kg twice daily every 2 weeks recommended dose 30 mg/kg twice daily ( 2.2 ) adults 16 years older : 500 mg twice daily ; increase 500 mg twice daily every 2 weeks recommended dose 1500 mg twice daily ( 2.2 ) myoclonic seizures adults pediatric patients 12 years older 500 mg twice daily ; increase 500 mg twice daily every 2 weeks recommended dose 1500 mg twice daily ( 2.3 ) primary generalized tonic-clonic seizures 6 years < 16 years : 10 mg/kg twice daily , increase increments 10 mg/kg twice daily every 2 weeks recommended dose 30 mg/kg twice daily ( 2.4 ) adults 16 years older : 500 mg twice daily , increase 500 mg twice daily every 2 weeks recommended dose 1500 mg twice daily ( 2.4 ) adult patients impaired renal function dose adjustment recommended , based patient \u2019 estimated creatinine clearance ( 2.5 , 8.6 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "product : 50090-7521 ndc : 50090-7521-0 120 tablet bottle ndc : 50090-7521-1 60 tablet bottle ndc : 50090-7521-2 90 tablet bottle ndc : 50090-7521-3 180 tablet bottle",
    "adverseReactions": "levetiracetam tablets contraindicated patients hypersensitivity levetiracetam . included anaphylaxis angioedema [ ( 5.4 ) ] .",
    "indications_original": "Levetiracetam is indicated for the treatment of partial-onset seizures in patients 1 month of age and older (1.1) Levetiracetam is indicated for adjunctive therapy for the treatment of: Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy (1.2) Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy (1.3)",
    "contraindications_original": "Use the oral solution for pediatric patients with body weight \u2264 20 kg (2.1) For pediatric patients, use weight-based dosing for the oral solution with a calibrated measuring device (not a household teaspoon or tablespoon) (2.1) Partial-Onset Seizures (monotherapy or adjunctive therapy) 1 Month to < 6 Months: 7 mg/kg twice daily; increase by 7 mg/kg twice daily every 2 weeks to recommended dose of 21 mg/kg twice daily (2.2) 6 Months to < 4 Years: 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 25 mg/kg twice daily (2.2) 4 Years to < 16 Years: 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily (2.2) Adults 16 Years and Older: 500 mg twice daily; increase by 500 mg twice daily every 2 weeks to a recommended dose of 1500 mg twice daily (2.2) Myoclonic Seizures in Adults and Pediatric Patients 12 Years and Older 500 mg twice daily; increase by 500 mg twice daily every 2 weeks to recommended dose of 1500 mg twice daily (2.3) Primary Generalized Tonic-Clonic Seizures 6 Years to < 16 Years: 10 mg/kg twice daily, increase in increments of 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily (2.4) Adults 16 Years and Older: 500 mg twice daily, increase by 500 mg twice daily every 2 weeks to recommended dose of 1500 mg twice daily (2.4) Adult Patients with Impaired Renal Function Dose adjustment is recommended, based on the patient\u2019s estimated creatinine clearance (2.5, 8.6)",
    "warningsAndPrecautions_original": "Product:    50090-7521\n                  NDC:    50090-7521-0   120 TABLET in a BOTTLE\n                  NDC:    50090-7521-1   60 TABLET in a BOTTLE\n                  NDC:    50090-7521-2   90 TABLET in a BOTTLE\n                  NDC:    50090-7521-3   180 TABLET in a BOTTLE",
    "adverseReactions_original": "Levetiracetam tablets are contraindicated in patients with a hypersensitivity to levetiracetam. Reactions have included anaphylaxis and angioedema [see \n                     \n                        Warnings and Precautions (5.4)\n                     \n                     ].",
    "drug": [
        {
            "name": "Levetiracetam",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6437"
        }
    ]
}